Inhibition of comt with tolcapone slows progression of polycystic kidney disease in the more severely affected PKD/Mhm (cy/+) substrain of the hannover sprague-dawley rat

Nephrology Dialysis Transplantation

Volumn 28, Issue 8, 2013, Pages 2045-2058

  Boehn, Susanne N E ^a   Spahn, Sonja ^a   Neudecker, Sabine ^a   Keppler, Andrea ^a   Bihoreau, Marie Thérèse ^b   Kränzlin, Bettina ^a   Pandey, Priyanka ^c   Hoffmann, Sigrid C ^a   Li, Li ^a   Torres, Vicente E ^d   Gröne, Hermann Josef ^e   Gretz, Norbert ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b CENTRE NATIONAL DE GÉNOTYPAGE   (France)

^c NATIONAL INSTITUTE OF BIOMEDICAL GENOMICS   (India)

^d Mayo Clinic College of Medicine   (United States)

^e GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Catechol O methyltransferase; Gene expression profiling; Modifier; Polycystic kidney disease; Tolcapone

Indexed keywords

CATECHOL METHYLTRANSFERASE; CYCLIC AMP; TOLCAPONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CATECHOL METHYLTRANSFERASE GENE; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DRUG RESPONSE; ENZYME INHIBITION; FEMALE; GENE EXPRESSION PROFILING; GENE LOCATION; KIDNEY FIBROSIS; KIDNEY POLYCYSTIC DISEASE; MALE; MITOSIS INHIBITION; NEPHRITIS; NONHUMAN; PRIORITY JOURNAL; RAT; STRAIN DIFFERENCE;

CATECHOL-O-METHYLTRANSFERASE; GENE EXPRESSION PROFILING; MODIFIER; POLYCYSTIC KIDNEY DISEASE; TOLCAPONE;

ANIMALS; APOPTOSIS; BENZOPHENONES; BIOLOGICAL MARKERS; BLOTTING, WESTERN; CATECHOL O-METHYLTRANSFERASE; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; ENZYME INHIBITORS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; NITROPHENOLS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYCYSTIC KIDNEY DISEASES; RATS; RATS, SPRAGUE-DAWLEY; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 84884576860     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gft014     Document Type: Article

References (75)

1. Torres VE, Harris PC. Autosomal dominant polycystic kidney disease: the last 3 years. Kidney Int 2009; 76: 149-168
2. Gabow PA. Autosomal dominant polycystic kidney disease- more than a renal disease. Am J Kidney Dis 1990; 16: 403-413
3. Cowley BD, Jr., Gudapaty S, Kraybill AL et al. Autosomal-dominant polycystic kidney disease in the rat. Kidney Int 1993; 43: 522-534
4. Igarashi P, Somlo S. Genetics and pathogenesis of polycystic kidney disease. J Am Soc Nephrol 2002; 13: 2384-2398
5. Yoder BK, Hou X, Guay-Woodford LM. The polycystic kidney disease proteins, polycystin-1, polycystin-2, polaris, and cystin, are co-localized in renal cilia. J Am Soc Nephrol 2002; 13: 2508-2516
6. Veland IR, Awan A, Pedersen LB et al. Primary cilia and signaling pathways in mammalian development, health and disease. Nephron Physiol 2009; 111: 39-53
7. Distefano G, Boca M, Rowe I et al. Polycystin-1 regulates extracellular signal-regulated kinase-dependent phosphorylation of tuberin to control cell size through mTOR and its downstream effectors S6K and 4EBP1. Mol Cell Biol 2009; 29: 2359-2371
8. Xia S, Li X, Johnson T et al. Polycystin-dependent fluid flow sensing targets histone deacetylase 5 to prevent the development of renal cysts. Development 2010; 137: 1075-1084
9. Chapin HC, Rajendran V, Caplan MJ. Polycystin-1 surface localization is stimulated by polycystin-2 and cleavage at the G protein-coupled receptor proteolytic site. Mol Biol Cell 2010; 21: 4338-4348
10. Peters DJ, Sandkuijl LA. Genetic heterogeneity of polycystic kidney disease in Europe. Contrib Nephrol 1992; 97: 128-139
11. Peters DJ, Breuning MH. Autosomal dominant polycystic kidney disease: modification of disease progression. Lancet 2001; 358: 1439-1444
12. Guay-Woodford LM, Wright CJ, Walz G et al. Quantitative trait loci modulate renal cystic disease severity in the mouse bpk model. J Am Soc Nephrol 2000; 11: 1253-1260
13. Bihoreau MT, Megel N, Brown JH et al. Characterization of a major modifier locus for polycystic kidney disease (Modpkdr1) in the Han:SPRD(cy/+) rat in a region conserved with a mouse modifier locus for Alport syndrome. Hum Mol Genet 2002; 11: 2165-2173
14. Gretz N, Ceccherini I, Kranzlin B et al. Gender-dependent disease severity in autosomal polycystic kidney disease of rats. Kidney Int 1995; 48: 496-500
15. Woo DD, Nguyen DK, Khatibi N et al. Genetic identification of two major modifier loci of polycystic kidney disease progression in pcy mice. J Clin Invest 1997; 100: 1934-1940
16. Harris PC. Molecular basis of polycystic kidney disease: PKD1, PKD2 and PKHD1. Curr Opin Nephrol Hypertens 2002; 11: 309-314
17. Hateboer N, Veldhuisen B, Peters B et al. Location of mutations within the PKD2 gene influences clinical outcome. Kidney Int 2000; 57: 1444-1451
18. Rossetti S, Burton S, Strmecki L et al. The position of the polycystic kidney disease 1 (PKD1) gene mutation correlates with the severity of renal disease. J Am Soc Nephrol 2002; 13: 1230-1237
19. Connor A, Lunt PW, Dolling C et al. Mosaicism in autosomal dominant polycystic kidney disease revealed by genetic testing to enable living related renal transplantation. Am J Transplant 2008; 8: 232-237
20. Rossetti S, Kubly VJ, Consugar MB et al. Incompletely penetrant PKD1 alleles suggest a role for gene dosage in cyst initiation in polycystic kidney disease. Kidney Int 2009; 75: 848-855
21. Gretz N. Progression of chronic renal failure in a rat strain with autosomal dominant polycystic kidney disease. Nephron Physiol 1994; 68: 462-467
22. Nagao S, Kusaka M, Nishii K et al. Androgen receptor pathway in rats with autosomal dominant polycystic kidney disease. J Am Soc Nephrol 2005; 16: 2052-2062
23. Anderson S, Oyama TT, Lindsley JN et al. 2-Hydroxyestradiol slows progression of experimental polycystic kidney disease. Am J Physiol Renal Physiol 2011
24. Iakoubova OA, Dushkin H, Beier DR. Localization of a murine recessive polycystic kidney disease mutation and modifying loci that affect disease severity. Genomics 1995; 26: 107-114
25. Kuida S, Beier DR. Genetic localization of interacting modifiers affecting severity in a murine model of polycystic kidney disease. Genome Res 2000; 10: 49-54
26. Iakoubova OA, Dushkin H, Beier DR. Genetic analysis of a quantitative trait in a mouse model of polycystic kidney disease. Am J Respir Crit Care Med 1997; 156: S72-S77
27. Upadhya P, Churchill G, Birkenmeier EH et al. Genetic modifiers of polycystic kidney disease in intersubspecific KAT2J mutants. Genomics 1999; 58: 129-137
28. Sommardahl C, Cottrell M, Wilkinson JE et al. Phenotypic variations of orpk mutation and chromosomal localization of modifiers influencing kidney phenotype. Physiol Genomics 2001; 7: 127-134
29. Mrug M, Li R, Cui X et al. Kinesin family member 12 is a candidate polycystic kidney disease modifier in the cpk mouse. J Am Soc Nephrol 2005; 16: 905-916
30. Schafer K, Gretz N, Bader M et al. Characterization of the Han: SPRD rat model for hereditary polycystic kidney disease. Kidney Int 1994; 46: 134-152
31. Bihoreau MT, Ceccherini I, Browne J et al. Location of the first genetic locus, PKDr1, controlling autosomal dominant polycystic kidney disease in Han:SPRD cy/+ rat. Hum Mol Genet 1997; 6: 609-613
32. Brown JH, Bihoreau MT, Hoffmann S et al. Missense mutation in sterile alpha motif of novel protein SamCystin is associated with polycystic kidney disease in (cy/+) rat. J Am Soc Nephrol 2005; 16: 3517-3526
33. Stagner EE, Bouvrette DJ, Cheng J et al. The polycystic kidney disease-related proteins Bicc1 and SamCystin interact. Biochem Biophys Res Commun 2009; 383: 16-21
34. Kugita M, Nishii K, Morita M et al. Global gene expression profiling in early-stage polycystic kidney disease in the Han:SPRD Cy rat identifies a role for RXR signaling. Am J Physiol Renal Physiol 2011; 300: F177-F188
35. Nagao S, Morita M, Kugita M et al. Polycystic kidney disease in Han:SPRD Cy rats is associated with elevated expression and mislocalization of SamCystin. Am J Physiol Renal Physiol 2010; 299: F1078-F1086
36. Neudecker S, Walz R, Menon K et al. Transgenic overexpression of Anks6(p.R823W) causes polycystic kidney disease in rats. Am J Pathol 2010; 177: 3000-3009
37. Männistö PT, Kaakkola S. Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors. Pharmacol Rev 1999; 51: 593-628
38. Schendzielorz N, Rysa A, Reenila I et al. Complex estrogenic regulation of catechol-O-methyltransferase (COMT) in rats. J Physiol Pharmacol 2011; 62: 483-490
39. Weisz J, Fritz-Wolz G, Clawson GA et al. Induction of nuclear catechol-O-methyltransferase by estrogens in hamster kidney: implications for estrogen-induced renal cancer. Carcinogenesis 1998; 19: 1307-1312
40. Cohn CK, Axelrod J. The effect of estradiol on catechol-O- methyltransferase activity in rat liver. Life Sci I 1971; 10: 1351-1354
41. Lajin B, Hamzeh AR, Ghabreau L et al. Catechol-O-methyltransferase Val 108/158 Met polymorphism and breast cancer risk: a case-control study in Syria. Breast Cancer 2011
42. Chang I, Liu J, Majid S et al. Catechol-O-methyltransferase-mediated metabolism of 4-hydroxyestradiol inhibits the growth of human renal cancer cells through the apoptotic pathway. Carcinogenesis 2012; 33: 420-426
43. Belibi FA, Edelstein CL. Novel targets for the treatment of autosomal dominant polycystic kidney disease. Expert Opin Investig Drugs 2010; 19: 315-328
44. Kaspareit-Rittinghausen J, Deerberg F, Rapp KG et al. A new rat model for polycystic kidney disease of humans. Transplant Proc 1990; 22: 2582-2583
45. Torres VE, Bengal RJ, Litwiller RD et al. Aggravation of polycystic kidney disease in Han:SPRD rats by buthionine sulfoximine. J Am Soc Nephrol 1997; 8: 1283-1291
46. Chu TM, Weir B, Wolfinger R. A systematic statistical linear modeling approach to oligonucleotide array experiments. Math Biosci 2002; 176: 35-51
47. Dai M, Wang P, Boyd AD et al. Evolving gene/transcript definitions significantly alter the interpretation of Gene Chip data. Nucleic Acids Res 2005; 33: e175
48. Maric C, Sandberg K, Hinojosa-Laborde C. Glomerulosclerosis and tubulointerstitial fibrosis are attenuated with 17beta-estradiol in the aging Dahl salt sensitive rat. J Am Soc Nephrol 2004; 15: 1546-1556
49. Mankhey RW et al. 17beta-estradiol supplementation reduces tubulointerstitial fibrosis by increasing MMP activity in the diabetic kidney. Am J Physiol Regul Integr Comp Physiol 2007; 292: R769-R777
50. Josefsson E, Tarkowski A, Carlsten H. Anti-inflammatory properties of estrogen. I. In vivo suppression of leukocyte production in bone marrow and redistribution of peripheral blood neutrophils. Cell Immunol 1992; 142: 67-78
51. Ogborn MR, Bankovic-Calic N, Shoesmith C et al. Soy protein modification of rat polycystic kidney disease. Am J Physiol 1998; 274: F541-F549
52. Thigpen JE, Setchell KD, Goelz MF et al. The phytoestrogen content of rodent diets. Environ Health Perspect 1999; 107: A182-A183
53. Thigpen JE, Setchell KD, Ahlmark KB et al. Phytoestrogen content of purified, open-and closed-formula laboratory animal diets. Lab Anim Sci 1999; 49: 530-536
54. van Duursen MB, Sanderson JT, de Jong PC et al. Phytochemicals inhibit catechol-O-methyltransferase activity in cytosolic fractions from healthy human mammary tissues: implications for catechol estrogen-induced DNA damage. Toxicol Sci 2004; 81: 316-324
55. Calvet JP, Grantham JJ. The genetics and physiology of polycystic kidney disease. Semin Nephrol 2001; 21: 107-123
56. Moser M, Pscherer A, Roth C et al. Enhanced apoptotic cell death of renal epithelial cells in mice lacking transcription factor AP-2beta. Genes Dev 1997; 11: 1938-1948
57. Fick-Brosnahan GM, Belz MM, McFann KK et al. Relationship between renal volume growth and renal function in autosomal dominant polycystic kidney disease: a longitudinal study. Am J Kidney Dis 2002; 39: 1127-1134
58. Grantham JJ, Torres VE, Chapman AB et al. Volume progression in polycystic kidney disease. N Engl J Med 2006; 354: 2122-2130
59. Gattone VH, II, Wang X, Harris PC et al. Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat Med 2003; 9: 1323-1326
60. Torres VE. Cyclic AMP, at the hub of the cystic cycle. Kidney Int 2004; 66: 1283-1285
61. Hanaoka K, Guggino WB. cAMP regulates cell proliferation and cyst formation in autosomal polycystic kidney disease cells. J Am Soc Nephrol 2000; 11: 1179-1187
62. Li H, Findlay IA, Sheppard DN. The relationship between cell proliferation, Cl-secretion, and renal cyst growth: a study using CFTR inhibitors. Kidney Int 2004; 66: 1926-1938
63. Nagao S, Yamaguchi T, Kusaka M et al. Renal activation of extracellular signal-regulated kinase in rats with autosomaldominant polycystic kidney disease. Kidney Int 2003; 63: 427-437
64. Wallace DP. Cyclic AMP-mediated cyst expansion. Biochim Biophys Acta 2011; 1812: 1291-1300
65. Marcocci L, Maguire JJ, Packer L. Nitecapone: a nitric oxide radical scavenger. Biochem Mol Biol Int 1994; 34: 531-541
66. Suzuki YJ, Packer L. Inhibition of NF-kappa B transcription factor by catechol derivatives. Biochem Mol Biol Int 1994; 32: 299-305
67. Suzuki YJ et al. Antioxidant properties of nitecapone (OR-462). Free Radic Biol Med 1992; 13: 517-525
68. Mervaala E, Muller DN, Schmidt F et al. Blood pressure-independent effects in rats with human renin and angiotensinogen genes. Hypertension 2000; 35: 587-594
69. Helkamaa T, Finckenberg P, Louhelainen M et al. Entacapone protects from angiotensin II-induced inflammation and renal injury. J Hypertens 2003; 21: 2353-2363
70. Lal MA, Korner A, Matsuo Y et al. Combined antioxidant and COMT inhibitor treatment reverses renal abnormalities in diabetic rats. Diabetes 2000; 49: 1381-1389
71. Tao Y, Kim J, Schrier RW et al. Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease. J Am Soc Nephrol 2005; 16: 46-51
72. Wang X, Gattone V, 2nd, Harris PC et al. Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat. J Am Soc Nephrol 2005; 16: 846-851
73. Bukanov NO, Smith LA, Klinger KW et al. Long-lasting arrest of murine polycystic kidney disease with CDK inhibitor roscovitine. Nature 2006; 444: 949-952
74. Sung B, Pandey MK, Aggarwal BB. Fisetin, an inhibitor of cyclindependent kinase 6, down-regulates nuclear factor-kappaB-regulated cell proliferation, antiapoptotic and metastatic gene products through the suppression of TAK-1 and receptor-interacting protein-regulated IkappaBalpha kinase activation. Mol Pharmacol 2007; 71: 1703-1714
75. Wahl PR, Serra AL, Le Hir M et al. Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD). Nephrol Dial Transplant 2006; 21: 598-604